Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

OBJECTIVES: To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID). METHODS: Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Martín-Varillas, José Luis, Sanchez-Bilbao, Lara, Calvo-Río, Vanesa, Adán, Alfredo, Hernanz, Inés, Gallego-Flores, Adela, Beltran-Catalan, Emma, Castro-Oreiro, Sonia, Fanlo, Patricia, Garcia Martos, Alvaro, Torre, Ignacio, Cordero-Coma, Miguel, De Dios, Juan Ramon, García-Aparicio, Ángel, Hernández-Garfella, Marisa, Sánchez-Andrade, Amalia, García-Valle, Andrea, Maiz, Olga, Miguélez, Roberto, Rodríguez-Montero, Sergio, Urruticoechea, Ana, Veroz, Raúl, Conesa, Arantxa, Fernández-Carballido, Cristina, Jovaní, Vega, Mondejar, Jose J, Martínez González, Olga, Moya Alvarado, Patricia, Romero-Yuste, Susana, Rubio-Muñoz, Paula, Peña-Sainz-Pardo, Eva, Garijo-Bufort, Marta, Demetrio-Pablo, Rosalía, Hernández, José L, Blanco, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Miscellaneous
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730404/
https://www.ncbi.nlm.nih.gov/pubmed/36597972
http://dx.doi.org/10.1136/rmdopen-2022-002693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730404/
https://www.ncbi.nlm.nih.gov/pubmed/36597972
http://dx.doi.org/10.1136/rmdopen-2022-002693

Ejemplares similares